Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuralgia, Diabetic Clear all
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 4 Interventional

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

NCT00194909
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
sildenafil (Viagra)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Sep 15, 2026, 1:02 AM EDT
Active, not recruiting Not applicable Interventional

Cryoneurolysis for Painful Diabetic Neuropathy of the Foot

NCT06646731
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
cryoneurolysis, sham cryoneurolysis
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT05986292
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Interventions
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904
View directory record Official record
Conditions
Neuralgia
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 15, 2026, 1:02 AM EDT
Active, not recruiting Not applicable Interventional

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

NCT03625752
View directory record Official record
Conditions
Diabetic Neuropathies, Chronic Pain
Interventions
Active Comparator: Active tDCS + Active TUS, Sham
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy for Diabetic Neuropathic Pain

NCT00829387
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBT plus standard pharmaceutical care (CBT/SC), Diabetic Education plus standard pharmaceutical care (ED/SC)
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 15, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

NCT01521598
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
SKL11197, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Northport, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional

Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy

NCT00781001
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 15, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial

NCT04087941
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
VM-202
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Phase 1 Interventional

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06361108
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
YJ001 for Spray Use, Placebo of YJ001 for Spray Use
Drug
Lead sponsor
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fredericksburg, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

NCT04455633
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetes
Interventions
LX9211, LX9211 Matching Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 15, 2026, 1:02 AM EDT
Not listed Not applicable Interventional

An Evaluation of an SCCD on the Symptomatology of Painful DPN

NCT03331614
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Flowaid FA-100 SCCD
Device
Lead sponsor
Rosenblum, Jonathan I., DPM
Individual
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lodi, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 15, 2026, 1:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 15, 2026, 1:02 AM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT04688671
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Interventions
ETX-018810, Placebo
Drug
Lead sponsor
Eliem Therapeutics (UK) Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 4 Interventional

Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

NCT00266643
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • Tallahassee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Sep 15, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 15, 2026, 1:02 AM EDT